Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis

CAMBRIDGE, Mass., April 4, 2018 -- (Healthcare Sales & Marketing Network) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic f... Biopharmaceuticals, FDA Proteostasis Therapeutics, transmembrane conductance regulator, cystic fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news